Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Nov 1;37(13):2097-2099.
doi: 10.1097/QAD.0000000000003653. Epub 2023 Jul 7.

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers

Kesner Francois  1 , Joelle Deas Van Onacker  1 , Michael R Jordan  2   3 , Ito Journel  4 , Josiane Buteaue  1 , Emmanuel Pierre  1 , Nirva Duval  1 , Georges Dos Santos  5 , Amalia Giron  6 , Harry Geffrard  7 , Omar Sued  7 , Seth C Inzaule  8
Affiliations
Case Reports

First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers

Kesner Francois et al. AIDS. .

Abstract

Perinatally HIV-infected infants can be infected with a drug-resistant virus or select for drug resistance by exposure to sub-therapeutic levels of maternal antiretroviral drugs present in breastmilk or from sub-therapeutic infant prophylaxis. We report a case of dolutegravir resistance detected in a treatment-naive perinatally HIV-infected infant whose mother was receiving tenofovir/lamivudine/dolutegravir. This case was detected during a national survey of HIV drug resistance in Haiti amongst infants testing positive for HIV through the national early infant diagnosis program between April 2020 and March 2021. This unique case underscores the need for prompt management of high viral loads in pregnant and breastfeeding women and supports HIV drug resistance surveillance efforts targeted at antiretroviral therapy-naive infants born to mothers in low-and middle-income countries.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Prevalence and patterns of HIV drug resistance-associated mutations among antiretroviral therapy-naive children less than 18 months of age newly diagnosed with HIV in Haiti.
See this image and copyright information in PMC

References

    1. World Health Organization (WHO). Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach 2021. 2021. Available at: https://www.who.int/publications/i/item/9789240031593. [Accessed 10 August 2021]
    1. Lockman S, Brummel SS, Ziemba L, Stranix-Chibanda L, McCarthy K, Coletti A, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2021; 397:1276–1292. - PMC - PubMed
    1. Kintu K, Malaba TR, Nakibuka J, Papamichael C, Colbers A, Byrne K, et al. DolPHIN-2 Study Group. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial. Lancet HIV 2020; 7:e332–e339. - PMC - PubMed
    1. Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta-analysis. EClinicalMedicine 2020; 28:100573. - PMC - PubMed
    1. Da Silva J, Vallabhaneni S, Pati R, Chun H, Malati C, Kiesa D, et al. Successful transition to tenofovir/lamivudine/dolutegravir (TLD) in PEPFAR-supported countries. International AIDS Society, Montreal Canada. 2022. Available at: https://programme.aids2022.org/Abstract/Abstract/?abstractid=10414. [Accessed 11 October 2022]

Publication types